Background Diagnostic requests for both Zika virus (ZIKV) and dengue virus (DENV) infections in returning travelers have significantly increased during the recent ZIKV outbreak in the Americás. These flaviviruses have overlapping clinical syndromes and geographical distribution, but diagnostic differentiation is important because of different clinical consequences. As flaviviruses are known to have a short viremic period, diagnostics often rely on serological methods, which are challenging due to extensive cross-reactive antibodies. Objective To re-evaluate the performance of DENV serological assays in laboratory confirmed ZIKV-infected travelers. Study design The extent of cross-reactivity of the DENV NS1 antigen, IgM and IgG ELISA was analyzed in 152 clinical blood samples collected from 69 qRT-PCR and 24 virus neutralization titer (VNT) confirmed ZIKV-infected travelers. Results The majority of travelers in the presented cohort returned to the Netherlands from Suriname and presented with symptoms of fever and rash. Twenty-three percent of the female travelers were pregnant. None of the 39 ZIKV RNA positive blood samples were cross-reactive in the DENV NS1 antigen ELISA. The rates of cross-reactivity of the DENV IgM and IgG ELISÁs were 31% and 54%, respectively, after excluding travelers with (potential) previous DENV exposure. Conclusions Although the DENV NS1 antigen assay was highly specific in this cohort of laboratory confirmed ZIKV-infected travelers, we demonstrate high percentages of cross-reactivity of DENV IgM and IgG ELISÁs of which diagnostic laboratories should be aware. In addition, the high rate of DENV IgG background of >25% complicates a proper serological diagnosis in this group.

Additional Metadata
Persistent URL,
Journal Journal of Clinical Virology
van Meer, M.P.A. (Maurits P.A.), Mögling, R, Klaasse, J. (Janienne), Chandler, F.D. (Felicity D.), Pas, S.D, Eijck, A.A, … Geurts van Kessel, C.H. (2017). Re-evaluation of routine dengue virus serology in travelers in the era of Zika virus emergence. Journal of Clinical Virology, 92, 25–31. doi:10.1016/j.jcv.2017.05.001